Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib or enasidenib plus azacitidine in newly diagnosed IDH-mutant AML unfit for intensive chemotherapy
2024-511722-31-00Phase 2Authorised
- Sponsor
- Celgene Corporation
- Start
- Nov 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial in acute myeloid leukemia (AML) comparing Ivosidenib plus azacitidine with Enasidenib mesylate plus azacitidine (2 arms). Planned start Nov 2016; status: authorised.
02
Drugs
ivosidenibenasidenibazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-511722-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511722-31-00.